Trends in the Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infections in Iranian Patients with Hereditary Bleeding Disorders.
HIV
Iran
blood safety
hemophilia A
hepatitis B
hepatitis C
Journal
Pathogens (Basel, Switzerland)
ISSN: 2076-0817
Titre abrégé: Pathogens
Pays: Switzerland
ID NLM: 101596317
Informations de publication
Date de publication:
04 Apr 2023
04 Apr 2023
Historique:
received:
02
02
2023
revised:
21
03
2023
accepted:
27
03
2023
medline:
28
4
2023
pubmed:
28
4
2023
entrez:
28
4
2023
Statut:
epublish
Résumé
Patients with hereditary bleeding disorders (HBDs) have always been vulnerable to transfusion-transmitted infections (TTIs) such as hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) infections due to being regular recipients of blood and blood products. This study aimed to detect the trends in the prevalence of HBV, HCV, and HIV infections by birthyear in Iranian patients with HBDs to show the efficacy of national interventions implemented to administrate control and to prevent these infections, i.e., blood safety, newborn HBV vaccination, and safe replacement treatments. In this retrospective study, the trends in the prevalence of hepatitis B core antibody (HBcAb), HCV antibody (HCV-Ab), and HIV antibody (HIV-Ab) in Iranian patients with HBDs born before 2012 were assessed using patients' clinical archives. The determinants of HBV, HCV, and HIV infections were investigated in bivariable and multivariable logistic regression analyses. Out of 1475 patients with HBDs, most were male (87.7%) and diagnosed with hemophilia A (52.1%) and severe bleeding disorder (63.7%). The prevalence of HBcAb, HCV-Ab, and confirmed HIV-Ab was 22.9%, 59.8%, and 1.2%, respectively. The trends in HBcAb, HCV-Ab, and HIV-Ab were all decreasing by birthyear and reached a stable level of 0% for patients with birthyears in 1999, 2000, and 1984, respectively. In multivariable analysis, birthyear was significantly associated with HBcAb prevalence. In the multivariable analysis, type of HBD; birthyear; bleeding severity; histories of receiving packed cells, fresh frozen plasma, and cryoprecipitate before 1996; and history of receiving factor concentrate before 1997 were highly associated with the prevalence of HCV-Ab. Moreover, in the bivariable analysis, birthyear and type of HBD were associated with HIV-Ab prevalence. This study demonstrated the decreasing trends in HBV, HCV, and HIV seroprevalence in Iranian patients with HBDs following preventive interventions such as HBV vaccination, blood safety measures, and the provision of safe replacement treatments.
Sections du résumé
BACKGROUND
BACKGROUND
Patients with hereditary bleeding disorders (HBDs) have always been vulnerable to transfusion-transmitted infections (TTIs) such as hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) infections due to being regular recipients of blood and blood products. This study aimed to detect the trends in the prevalence of HBV, HCV, and HIV infections by birthyear in Iranian patients with HBDs to show the efficacy of national interventions implemented to administrate control and to prevent these infections, i.e., blood safety, newborn HBV vaccination, and safe replacement treatments.
METHODS
METHODS
In this retrospective study, the trends in the prevalence of hepatitis B core antibody (HBcAb), HCV antibody (HCV-Ab), and HIV antibody (HIV-Ab) in Iranian patients with HBDs born before 2012 were assessed using patients' clinical archives. The determinants of HBV, HCV, and HIV infections were investigated in bivariable and multivariable logistic regression analyses.
RESULTS
RESULTS
Out of 1475 patients with HBDs, most were male (87.7%) and diagnosed with hemophilia A (52.1%) and severe bleeding disorder (63.7%). The prevalence of HBcAb, HCV-Ab, and confirmed HIV-Ab was 22.9%, 59.8%, and 1.2%, respectively. The trends in HBcAb, HCV-Ab, and HIV-Ab were all decreasing by birthyear and reached a stable level of 0% for patients with birthyears in 1999, 2000, and 1984, respectively. In multivariable analysis, birthyear was significantly associated with HBcAb prevalence. In the multivariable analysis, type of HBD; birthyear; bleeding severity; histories of receiving packed cells, fresh frozen plasma, and cryoprecipitate before 1996; and history of receiving factor concentrate before 1997 were highly associated with the prevalence of HCV-Ab. Moreover, in the bivariable analysis, birthyear and type of HBD were associated with HIV-Ab prevalence.
CONCLUSION
CONCLUSIONS
This study demonstrated the decreasing trends in HBV, HCV, and HIV seroprevalence in Iranian patients with HBDs following preventive interventions such as HBV vaccination, blood safety measures, and the provision of safe replacement treatments.
Identifiants
pubmed: 37111441
pii: pathogens12040555
doi: 10.3390/pathogens12040555
pmc: PMC10141030
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
PLoS One. 2016 Sep 09;11(9):e0162492
pubmed: 27611688
PLoS One. 2017 Jun 9;12(6):e0178883
pubmed: 28598970
Br J Haematol. 2021 Oct;195(2):174-185
pubmed: 33955555
Haemophilia. 2019 May;25(3):447-455
pubmed: 30866172
Ann Saudi Med. 2008 Nov-Dec;28(6):453-5
pubmed: 19011319
Saudi Med J. 2007 Oct;28(10):1516-9
pubmed: 17914511
Dev Biol Stand. 1993;81:147-61
pubmed: 8174797
Ann Intern Med. 2012 Dec 4;157(11):817-22
pubmed: 22910836
Blood. 2006 Feb 1;107(3):892-7
pubmed: 16204310
Transfusion. 2001 Mar;41(3):338-43
pubmed: 11274587
Gut. 2000 Dec;47(6):845-51
pubmed: 11076885
Iran Red Crescent Med J. 2012 Aug;14(8):470-4
pubmed: 23105982
Transfus Med. 2007 Dec;17(6):425-33
pubmed: 18067646
Virol J. 2021 Oct 7;18(1):199
pubmed: 34620204
Am J Epidemiol. 2007 Jun 15;165(12):1443-53
pubmed: 17379617
Arch Iran Med. 2020 Mar 01;23(3):189-196
pubmed: 32126788
Sci Rep. 2018 Jan 9;8(1):150
pubmed: 29317673
Braz J Infect Dis. 2019 Nov - Dec;23(6):419-426
pubmed: 31678055
J Clin Lab Anal. 2017 Jul;31(4):
pubmed: 27735085
Transfus Apher Sci. 2015 Aug;53(1):38-47
pubmed: 25892591
Hepat Mon. 2016 Apr 18;16(4):e37089
pubmed: 27275164
Hepat Mon. 2012 Apr;12(4):244-52
pubmed: 22690231